ENMD-2076 for hematological malignancies

Expert Opinion on Investigational Drugs

Volumn 21, Issue 5, 2012, Pages 717-732

  How, Jonathan ^a   Yee, Karen ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Acute myeloid leukemia; Aurora kinase inhibitors; ENMD 2076; Hematological malignancies; Multiple myeloma

Indexed keywords

AURORA A KINASE; CD135 ANTIGEN; ENMD 2076; PHOSPHOTRANSFERASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; SYSTEMATIC REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84859699770     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.668882     Document Type: Article

References (168)

1. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54 (Pubitemid 37411723)
2. Kimura M, Kotani S, Hattori T, et al. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem 1997;272:13766-71 (Pubitemid 27224814)
3. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. Embo J 1998;17:3052-65 (Pubitemid 28254378)
4. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93 (Pubitemid 28455454)
5. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96 (Pubitemid 47517082)
6. Honda K, Mihara H, Kato Y, et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000;19:2812-19 (Pubitemid 30386417)
7. Taguchi S, Honda K, Sugiura K, et al. Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett 2002;519:59-65 (Pubitemid 34521992)
8. Lindon C, Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol 2004;164:233-41 (Pubitemid 38133943)
9. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10
10. Liu Q, Kaneko S, Yang L, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004;279:52175-82 (Pubitemid 39656591)
11. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010;10:825-41
12. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106-11 (Pubitemid 47181586)
13. Lu LY, Wood JL, Ye L, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem 2008;283:31785-90
14. Sasai K, Parant JM, Brandt ME, et al. Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 2008;27:4122-7 (Pubitemid 351931992)
15. Cowley DO, Rivera-Perez JA, Schliekelman M, et al. Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol 2009;29:1059-71
16. Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindle checkpoint. Science 1995;267:1353-6
17. Yu X, Minter-Dykhouse K, Malureanu L, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 2005;37:401-6.
18. Fu Z, Regan K, Zhang L, et al. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Clin Invest 2009;119:2714-24
19. Mao JH, Wu D, Perez-Losada J, et al. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 2007;11:161-73. (Pubitemid 46209850)
20. Carmena M, Ruchaud S, Earnshaw WC. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol 2009;21:796-805
21. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869-75 (Pubitemid 44974478)
22. Lin YS, Su LJ, Yu CT, et al. Gene expression profiles of the aurora family kinases. Gene Expr 2006;13:15-26
23. Bernard M, Sanseau P, Henry C, et al. Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter. Genomics 1998;53:406-9 (Pubitemid 28527647)
24. Yang KT, Li SK, Chang CC, et al. Aurora-C kinase deficiency causes cytokinesis failure in meiosis I and production of large polyploid oocytes in mice. Mol Biol Cell 2010;21:2371-83
25. Tseng TC, Chen SH, Hsu YP, Tang TK. Protein kinase profile of sperm and eggs: cloning and characterization of two novel testis-specific protein kinases (AIE1, AIE2) related to yeast and fly chromosome segregation regulators. DNA Cell Biol 1998;17:823-33
26. Kimmins S, Crosio C, Kotaja N, et al. Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol 2007;21:726-39
27. Dieterich K, Soto Rifo R, Faure AK, et al. Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and causes male infertility. Nat Genet 2007;39:661-5 (Pubitemid 46676111)
28. Dieterich K, Zouari R, Harbuz R, et al. The Aurora Kinase C c.144delC mutation causes meiosis I arrest in men and is frequent in the North African population. Hum Mol Genet 2009;18:1301-9
29. Slattery SD, Mancini MA, Brinkley BR, Hall RM. Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle 2009; 8:2984-94
30. Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63 (Pubitemid 40012993)
31. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007;6:1851-7 (Pubitemid 46954062)
32. Kobayashi M, Nakamura S, Ono T, et al. Analysis of Aurora kinase expressions and cell cycle regulation by Aurora-C in leukemia cells. Blood 2006;108
33. Ochi T, Fujiwara H, Suemori K, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009;113:66-74
34. Ye D, Garcia-Manero G, Kantarjian HM, et al. Analysis of Aurora kinase a expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2009;2:2-8
35. Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, et al. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res 2011;35:260-4
36. Inamdar KV, O'Brien S, Sen S, et al. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. Mod Pathol 2008;21:1428-35
37. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7 (Pubitemid 38667616)
38. Huang XF, Luo SK, Xu J, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008;111:2854-65
39. McLaughlin J, Markovtsov V, Li H, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010;136:99-113
40. Ikezoe T, Yang J, Nishioka C, Yokoyama A. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. Int J Hematol 2010;91:69-77
41. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-40 (Pubitemid 47443920)
42. Oke A, Pearce D, Wilkinson RW, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res 2009;69:4150-8
43. Walsby E, Walsh V, Pepper C, et al. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008;93:662-9 (Pubitemid 351669305)
44. Hardwicke MA, Oleykowski CA, Plant R, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009;8:1808-17
45. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938-46
46. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17
47. Kojima K, Konopleva M, Tsao T, et al. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008;112:2886-95
48. Grundy M, Seedhouse C, Shang S, et al. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 2010;9:661-72
49. Tanaka R, Squires MS, Kimura S, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010;116:2089-95
50. Kelly KR, Ecsedy J, Medina E, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2011;15:2057-70
51. Donato NJ, Fang D, Sun H, et al. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol 2010;79:688-97
52. Okabe S, Tauchi T, Ohyashiki JH, Ohyashiki K. Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. Biochem Biophys Res Commun 2009;380:775-9
53. Gontarewicz A, Balabanov S, Keller G, et al. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leuk Res 2008;32:1857-65
54. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCRABL mutations including T315I. Blood 2008;111:4355-64
55. Fei F, Stoddart S, Groffen J, Heisterkamp N. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Ablpositive acute lymphoblastic leukemias. Mol Cancer Ther 2010;9:1318-27
56. Grundy M, Seedhouse C, Russell NH, Pallis M. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA. BMC Cancer 2011;11:254
57. Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008;112:793-804
58. Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol 2010;89:1081-7
59. Fiskus W, Wang Y, Joshi R, et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008;14:6106-15.
60. Cheong JW, Jung HI, Eom JI, et al. Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe. Cancer Lett 2010;297:171-81
61. Yakushijin Y, Hamada M, Yasukawa M. The expression of the aurora-A gene and its significance with tumorgenesis in non-Hodgkin's lymphoma. Leuk Lymphoma 2004;45:1741-6 (Pubitemid 38997139)
62. Hamada M, Yakushijin Y, Ohtsuka M, et al. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. Br J Haematol 2003;121:439-47 (Pubitemid 36628335)
63. Camacho E, Bea S, Salaverria I, et al. Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer 2006;118:357-63 (Pubitemid 41779075)
64. den Hollander J, Rimpi S, Doherty JR, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010;116:1498-505
65. Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia 2011;25:348-58
66. Sander B, Flygare J, Porwit-Macdonald A, et al. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int J Cancer 2005;117:418-30 (Pubitemid 41429565)
67. Mori N, Ishikawa C, Senba M, et al. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochem Pharmacol 2011;81:1106-15
68. Ikezoe T, Takeuchi T, Yang J, et al. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009;89:1364-73
69. Yang D, Liu H, Goga A, et al. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA 2010;107:13836-41
70. Goga A, Yang D, Tward AD, et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007;13:820-7 (Pubitemid 47038193)
71. Hoglund A, Nilsson LM, Forshell LP, et al. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009;113:4281-8
72. Qi W, Liu X, Cooke LS, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer 2011; Epub ahead of print
73. Qi W, Cooke LS, Liu X, et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 2011;81:881-90
74. Chng WJ, Ahmann GJ, Henderson K, et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006;107:3669-75
75. Chng WJ, Braggio E, Mulligan G, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008;111:1603-9 (Pubitemid 351213451)
76. Hose D, Reme T, Meissner T, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009;113:4331-40
77. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011;96:87-95
78. Evans RP, Naber C, Steffler T, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140:295-302
79. Shi Y, Reiman T, Li W, et al. Targeting aurora kinases as therapy in multiple myeloma. Blood 2007;109:3915-21 (Pubitemid 46641744)
80. Santo L, Hideshima T, Cirstea D, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res 2011;17:3259-71
81. Gorgun G, Calabrese E, Hideshima T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115:5202-13
82. Negri JM, McMillin DW, Delmore J, et al. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 2009;147:672-6
83. Evans R, Naber C, Steffler T, et al. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008;49:559-69 (Pubitemid 351298342)
84. Wang X, Sinn AL, Pollok K, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 2010;150:313-25.
85. Wang X, Sinn AL, Suvannasankha A, et al. The novel Aurora kinase inhibitor ENMD-2076 has potent single agent activity against multiple myeloma (MM) in vitro and in vivo, and shows synergistic activity in combination with lenalidomide. Blood 2008;112
86. Yoshida A, Zokumasu K, Yamauchi T, et al. Marked upregulations of survivin and aurora-B kinase are associated with disease progression in the myelodysplastic syndromes. Blood 2011;118:1633
87. Dawson MA, Curry JE, Barber K, et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010;150:46-57
88. Coumar MS, Cheung CH, Chang JY, Hsieh HP. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Patent 2009;19:321-56
89. Fletcher GC, Brokx RD, Denny TA, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011;10:126-37
90. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010;16:2989-98
91. Hembrough TA, Chen X, Burke PA, et al. Inhibition of multiple myeloma tumor growth and FGFR3 by the Aurora-angiogenesis inhibitor ENMD-981693. Blood 2007;110:366a
92. Fletcher GC, Brokx RD, Denny TA, et al. ENMD-2076 Is an Orally-Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action. Mol Cancer Ther 2010
93. Diamond JR, Bastos BR, Hansen RJ, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17:849-60
94. Yee KWL, Chen H-WT, Brandwein J, et al. A phase I study of ENMD-2076 in patients with relapsed or refractory leukemia. Blood 2010;116:1355
95. Farag S, Zhang S, Suvannasankha A, et al. Clinical activity of a novel multiple tyrosine kinase and Aurora kinase inhibitor, ENMD-2076, against multiple myeloma: Interim phase I trial results. Blood 2010;116:816
96. Matulonis U, Tew WP, Matei D, et al. A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. J Clin Oncol 2011;29:3375
97. Pollard JR, Mortimore M. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009;52:2629-51
98. Hook KE, Garza SJ, Lira ME, et al. An integrated genomic approach to identify predictive biomarkers of response to the Aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012; Epub ahead of print
99. Chowdhury A, Chowdhury S, Tsai MY. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma 2011; Epub ahead of print
100. Renshaw JS, Patnaik A, Gordon M, et al. A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results. J Clin Oncol 2007;25:6225
101. Sonet A, Graux C, Maertens J, et al. Phase I, dose-escalation study of 2 dosing regimens of AS703569, an Inhibitor of Aurora and other kinases, administered orally in patients with advanced hematological malignancies. Blood 2008;112:1018
102. AS703569 and gemcitabine combination in advanced malignancies. ClinicalTrialsgov 2010. Available from: http://clinicaltrials.gov/show/ NCT01097512 [Cited 11 November 2010]
103. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
104. Foran JM, Ravandi F, O'Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2008;26:1165
105. Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2011[Epub a head print]
106. Foote KM, Mortlock AA, Heron NM, et al. The discovery of AZD1152: a novel and highly potent aurora kinase. Proceedings of the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer, Molecular Targets and Therapeutics; 2005. p. 267
107. Boss DS, Witteveen PO, van der Sar J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011;22:431-7
108. Lowenberg B, Muus P, Ossenkoppele G, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011;118:6030-6
109. Study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC). ClinicalTrialsgov 2009. Available from: http://clinicaltrials.gov/show/NCT00926731 [Cited 11 November 2010]
110. Study to investigate the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in acute myeloid leukaemia (AML) patients (SPARKAML1). ClinicalTrialsgov 2009. Available from: http://clinicaltrials.gov/show/NCT00952588 [Cited 11 November 2010]
111. An open label, single centre mass balance C14 study in patients with acute myeloid leukaemia (AML). ClinicalTrialsgov 2009. Available from: http://clinicaltrials. gov/show/NCT01019161 [Cited 11 November 2010]
112. Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase I study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside in patients with acute myeloid leukemia (AML). Blood 2010;116:287
113. Keen N, Brown E, Crafter C, et al. Biological characterisation of AZD1152, a highly potent and selective inhibitor of aurora kinase activity. Proceedings of the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer, Molecular Targets and Therapeutics; 2005. p. 183
114. Gurtler U, Tontsch-Grunt U, Jarvis M, et al. Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis. J Clin Oncol 2010;28:e13632
115. Mross KB, Scheulen ME, Frost A, et al. A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors. J Clin Oncol 2010;28:235s
116. Scheulen ME, Mross KB, Richly H, et al. A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors. J Clin Oncol 2010;28:e13065
117. Hajduch M, Vydra D, Dzubak P, et al. In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008:abstract 5645
118. A phase I pharmacologic study of CYC116, an oral Aurora kinase inhibitor, in patients with advanced solid tumors. ClinicalTrialsgov 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00560716 [Cited 9 January 2011]
119. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51 (Pubitemid 44886012)
120. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15:6694-701
121. Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358), a multi-Kinase Aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2009;114
122. Laffranchi B, De Jonge MJ, Bajetta E, et al. Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). J Clin Oncol 2010;28:13558
123. Rosen PJ, Tolcher AW, Lee P, et al. Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors. J Clin Oncol 2010;28:249s
124. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27:5094-101
125. Gallerani E, Delord J, Schoffski P, et al. Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). J Clin Oncol 2010;28:393s
126. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68
127. Bleuse JP, Meulenbeld HJ, Vinci EM, et al. Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011;29:320s
128. Diamond JR, Bastos BR, Hansen RJ, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17:849-60
129. Phase I study of pharmacokinetics and pharmacodynamics of Aurora B/C kinase inhibitor GSK1070916A in patients with advanced solid tumors ClinicalTrialsgov 2010. Available from: http://clinicaltrials. gov/ct/show/NCT01118611 [Cited 11 November 2010]
130. Anderson K, Lai Z, McDonald OB, et al. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J 2009;420:259-65
131. Adams ND, Adams JL, Burgess JL, et al. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem 2010;53:3973-4001
132. Minton SE, LoRusso P, Lockhart AC, et al. A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 2010;28:13026
133. Shimomura T, Hasako S, Nakatsuru Y, et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 2010;9:157-66
134. Phase I study evaluating MK6592 in combination with docetaxel in adult patients with relapsed or refractory advanced solid tumors. ClinicalTrialsgov 2006. Available from: http://clinicaltrials. gov/show/NCT00359671 [Cited 9 January 2011]
135. Macarulla T, Cervantes A, Elez E, et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010;9:2844-52
136. Dees EC, Infante JR, Cohen RB, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:945-54
137. Manfredi MG, Ecsedy JA, Chakravarty A, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011;17:7614-24
138. Cervantes-Ruiperez A, Burris HA III, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors. J Clin Oncol 2010;28:240s
139. Cervantes-Ruiperez A, Elez ME, Rosello S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2009;27:124s
140. Dees EC, Infante JR, Burris HA, et al. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. J Clin Oncol 2010. 28
141. Aurora A kinase inhibitor MLN8237 and bortezomib in treating patients with relapsed or refractory multiple myeloma. ClinicalTrialsgov 2009. Available from: http://clinicaltrials.gov/show/NCT01034553 [Cited 11 November 2010]
142. MLN8237 in adults with nonhematological malignancies, followed by MLN8237 in lung, breast, head and neck or gastroesophageal malignancies. ClinicalTrialsgov 2010. Available from: http://clinicaltrials.gov/show/ NCT01045421 [Cited 11 November 2010]
143. MLN8237 in patients with ovarian, fallopian tube or peritoneal cancer preceded by Phase 1 study of MLN8237 plus paclitaxel treatment of ovary or breast cancer. ClinicalTrialsgov 2010. Available from: http://clinicaltrials. gov/show/NCT01091428 [Cited 11 November 2010]
144. Study of MLN8237 in patients with castration-resistant prostate cancer receiving a standard docetaxel/prednisone regimen. ClinicalTrialsgov 2010. Available from: http://clinicaltrials.gov/show/NCT01094288 [Cited 11 November 2010]
145. Study of MLN8237 in patients with advanced hematological malignancies ClinicalTrialsgov 2008. Available from: http://clinicaltrials.gov/show/ NCT00697346 [Cited 11 November 2010]
146. Study of an oral formulation of MLN8237 in patients with advanced solid tumors. ClinicalTrialsgov 2009. Available from: http://clinicaltrials.gov/show/ NCT00962091 [Cited 11 November 2010]
147. Padmanabhan S, Shea TC, Vose JM, et al. Phase I study of an investigational Aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies. Blood 2010;116:1154
148. Goldberg SL, Fenaux P, Craig MD, et al. Phase 2 study of MLN8237, an investigational Aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood 2010;116:341
149. Sharma S, Kurzrock R, Gouw L, et al. Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. J Clin Oncol 2011;29:2175
150. Schoffski P, Jones SF, Dumez H, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 2011;47:2256-64
151. Jani JP, Arcari J, Bernardo V, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9:883-94
152. Robert F, Verschraegen C, Hurwitz H, et al. A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol 2009;27:117s
153. Oslob JD, Romanowski MJ, Allen DA, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett 2008;18:4880-4
154. Godl K, Gruss OJ, Eickhoff J, et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 2005;65:6919-26 (Pubitemid 41060731)
155. Britten CD, Rosen LS, Kabbinavar F, et al. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers. Proceedings of the American Society of Clinical Oncology; 2002. p. 21
156. Sessa C, Vigano L, Grasselli G, et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 2006;42:171-8 (Pubitemid 43083486)
157. Kuenen BC, Giaccone G, Ruijter R, et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005;11:6240-6 (Pubitemid 41262954)
158. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007-14 (Pubitemid 43168337)
159. Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-2 (Pubitemid 46105945)
160. Giles F, Freedman SJ, Xiao A, et al. MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL. Blood 2006;108:556a
161. Giles F, Bergstrom DA, Garcia-Manero G, et al. MK-0457 is a novel Aurora kinase and Janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). Blood 2006;108:309b
162. Rubin EH, Shapiro GI, Stein MN, et al. A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients. J Clin Oncol 2006;24:123s
163. Papayannidis C, Iacobucci I, Soverini S, et al. Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol 2009;27:375s
164. Cortes J, Paquette R, Talpaz M, et al. Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/Aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood 2008;112:1109-10
165. Smith DC, Britten C, Garon EB, et al. A phase I study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma. J Clin Oncol 2010;28:259s
166. Smith DC, Britten C, Clary DO, et al. A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 2009;27:149s
167. Ravandi F, Foran J, Verstovsek S, et al. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. Blood 2007;110:275a-276a
168. Cortes J, Roboz GJ, Kantarjian HM, et al. A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Blood 2008;112:1019